Evidence map›Paper›PMID 40076468›Full record

SynthesisInternational journal of molecular sciences2025

The Diagnostic Role of the Platelet-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis.

Magdalena Bizon, Maciej Olszewski, Boguslawa Krason, Elzbieta Kochanowicz, Kamil Safiejko, Anna Borowka, Joanna Sekita-Krzak, Michal Pruc, Anna Drozd, Stepan Feduniw and 2 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Magdalena BizonDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.ORCID 0000-0001-9513-106X
Maciej OlszewskiDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.ORCID 0000-0003-2295-633X
Boguslawa KrasonDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.ORCID 0009-0004-2931-465X
Elzbieta KochanowiczInstitute of Biological Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
Kamil SafiejkoDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.
Anna BorowkaCollegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
Joanna Sekita-KrzakInstitute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
Michal PrucDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.ORCID 0000-0002-2140-9732
Anna DrozdDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.ORCID 0000-0003-0251-7495
Stepan FeduniwDepartment of Gynecology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-7746-8443
Basar CanderDepartment of Emergency Medicine, Bezmialem Vakif University, Fatih, 34093 Istanbul, Turkey.
Lukasz SzarpakDepartment of Clinical Research and Development, LUXMED Group, 02-678 Warsaw, Poland.ORCID 0000-0002-0973-5455

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is among the most lethal gynecologic malignancies, often diagnosed at advanced stages due to a lack of effective screening tools. Recent studies suggest that the platelet-to-lymphocyte ratio (PLR), an indicator of systemic inflammation, may serve as a potential biomarker for diagnosing and staging ovarian cancer. We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. We searched the PubMed/Medline, Scopus, Web of Science, and EMBASE databases. We pooled data using a random-effects model to assess the sensitivity, specificity, and diagnostic performance of PLR in ovarian cancer. The meta-analysis of 22 studies comprising 5740 participants showed significantly elevated platelet-to-lymphocyte ratio (PLR) values in ovarian cancer patients compared to healthy controls, with a mean difference of 46.84 (

Indexed as

Blood PlateletsLymphocytesOvarian NeoplasmsBiomarkers, TumorFemaleHumansLymphocyte CountNeoplasm StagingPlatelet CountBiomarkers, Tumorbiomarkermeta-analysisovarian cancerplatelet-to-lymphocyte ratiosystematic review

Identifiers

PMID40076468
PMCPMC11899326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.